Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma

M. Villa, GG. Sharma, F. Malighetti, M. Mauri, G. Arosio, N. Cordani, C. Lobello, H. Larose, A. Pirola, D. D'Aliberti, L. Massimino, L. Criscuolo, L. Pagani, C. Chinello, C. Mastini, D. Fontana, S. Bombelli, R. Meneveri, F. Lovisa, L. Mussolin,...

. 2024 ; 131 (11) : 1781-1795. [pub] 20241030

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003186

Grantová podpora
IG-22082 Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
2022XPF8A5 Ministero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research)
IG-20112 Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
R01 CA196703 NCI NIH HHS - United States
IG-24828 Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)

E-zdroje Online Plný text

NLK Free Medical Journals od 1947 do Před 1 rokem
Freely Accessible Journals od 1947 do Před 1 rokem
PubMed Central od 1947 do Před 1 rokem
Europe PubMed Central od 1947 do Před 1 rokem
ProQuest Central od 2000-01-01 do Před 1 rokem
Open Access Digital Library od 1947-01-01
Open Access Digital Library od 1999-01-01
Nursing & Allied Health Database (ProQuest) od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest) od 2000-01-01 do Před 1 rokem

Odkazy

PubMed 39478125
DOI 10.1038/s41416-024-02881-7
Knihovny.cz E-zdroje

BACKGROUND: Anaplastic Large Cell Lymphoma (ALCL) is a rare and aggressive T-cell lymphoma, classified into ALK-positive and ALK-negative subtypes, based on the presence of chromosomal translocations involving the ALK gene. The current standard of treatment for ALCL is polychemotherapy, with a high overall survival rate. However, a subset of patients does not respond to or develops resistance to these therapies, posing a serious challenge for clinicians. Recent targeted treatments such as ALK kinase inhibitors and anti-CD30 antibody-drug conjugates have shown promise but, for a fraction of patients, the prognosis is still unsatisfactory. METHODS: We investigated the genetic landscape of ALK + ALCL by whole-exome sequencing; recurring mutations were characterized in vitro and in vivo using transduced ALCL cellular models. RESULTS: Recurrent mutations in FAT family genes and the transcription factor RUNX1T1 were found. These mutations induced changes in ALCL cells morphology, growth, and migration, shedding light on potential factors contributing to treatment resistance. In particular, FAT4 silencing in ALCL cells activated the β-catenin and YAP1 pathways, which play crucial roles in tumor growth, and conferred resistance to chemotherapy. Furthermore, STAT1 and STAT3 were hyper-activated in these cells. Gene expression profiling showed global changes in pathways related to cell adhesion, cytoskeletal organization, and oncogenic signaling. Notably, FAT mutations associated with poor outcome in patients. CONCLUSIONS: These findings provide novel insights into the molecular portrait of ALCL, that could help improve treatment strategies and the prognosis for ALCL patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003186
003      
CZ-PrNML
005      
20250206104106.0
007      
ta
008      
250121s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41416-024-02881-7 $2 doi
035    __
$a (PubMed)39478125
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Villa, Matteo $u Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy $1 https://orcid.org/000000026534642X
245    10
$a Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma / $c M. Villa, GG. Sharma, F. Malighetti, M. Mauri, G. Arosio, N. Cordani, C. Lobello, H. Larose, A. Pirola, D. D'Aliberti, L. Massimino, L. Criscuolo, L. Pagani, C. Chinello, C. Mastini, D. Fontana, S. Bombelli, R. Meneveri, F. Lovisa, L. Mussolin, A. Janikova, Š. Pospíšilová, SD. Turner, G. Inghirami, F. Magni, M. Urso, F. Pagni, D. Ramazzotti, R. Piazza, R. Chiarle, C. Gambacorti-Passerini, L. Mologni
520    9_
$a BACKGROUND: Anaplastic Large Cell Lymphoma (ALCL) is a rare and aggressive T-cell lymphoma, classified into ALK-positive and ALK-negative subtypes, based on the presence of chromosomal translocations involving the ALK gene. The current standard of treatment for ALCL is polychemotherapy, with a high overall survival rate. However, a subset of patients does not respond to or develops resistance to these therapies, posing a serious challenge for clinicians. Recent targeted treatments such as ALK kinase inhibitors and anti-CD30 antibody-drug conjugates have shown promise but, for a fraction of patients, the prognosis is still unsatisfactory. METHODS: We investigated the genetic landscape of ALK + ALCL by whole-exome sequencing; recurring mutations were characterized in vitro and in vivo using transduced ALCL cellular models. RESULTS: Recurrent mutations in FAT family genes and the transcription factor RUNX1T1 were found. These mutations induced changes in ALCL cells morphology, growth, and migration, shedding light on potential factors contributing to treatment resistance. In particular, FAT4 silencing in ALCL cells activated the β-catenin and YAP1 pathways, which play crucial roles in tumor growth, and conferred resistance to chemotherapy. Furthermore, STAT1 and STAT3 were hyper-activated in these cells. Gene expression profiling showed global changes in pathways related to cell adhesion, cytoskeletal organization, and oncogenic signaling. Notably, FAT mutations associated with poor outcome in patients. CONCLUSIONS: These findings provide novel insights into the molecular portrait of ALCL, that could help improve treatment strategies and the prognosis for ALCL patients.
650    _2
$a lidé $7 D006801
650    12
$a anaplastický velkobuněčný lymfom $x genetika $x patologie $x farmakoterapie $7 D017728
650    _2
$a prognóza $7 D011379
650    12
$a mutace $7 D009154
650    12
$a kadheriny $x genetika $7 D015820
650    _2
$a myši $7 D051379
650    _2
$a zvířata $7 D000818
650    _2
$a fenotyp $7 D010641
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a sekvenování exomu $7 D000073359
655    _2
$a časopisecké články $7 D016428
700    1_
$a Sharma, Geeta G $u Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
700    1_
$a Malighetti, Federica $u Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy $1 https://orcid.org/0009000924928974
700    1_
$a Mauri, Mario $u Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
700    1_
$a Arosio, Giulia $u Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
700    1_
$a Cordani, Nicoletta $u Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
700    1_
$a Lobello, Cosimo $u Center of Molecular Medicine, Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic
700    1_
$a Larose, Hugo $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK
700    1_
$a Pirola, Alessandra $u Galseq srl, Bresso, Italy
700    1_
$a D'Aliberti, Deborah $u Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
700    1_
$a Massimino, Luca $u Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy $u Division of Immunology, Transplantation and Infectious Disease, IRCCS Ospedale San Raffaele, Milano, Italy
700    1_
$a Criscuolo, Lucrezia $u Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
700    1_
$a Pagani, Lisa $u Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
700    1_
$a Chinello, Clizia $u Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
700    1_
$a Mastini, Cristina $u Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
700    1_
$a Fontana, Diletta $u Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy $1 https://orcid.org/0000000316336310
700    1_
$a Bombelli, Silvia $u Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy $u Neurogenomics Research Center, Fondazione Human Technopole, Milano, Italy
700    1_
$a Meneveri, Raffaella $u Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
700    1_
$a Lovisa, Federica $u Maternal and Child Health, Department Pediatric Hematology, Oncology and Stem Cell Transplant Center, University of Padua, Padua, Italy $u Pediatric Research Institute "Città della Speranza", Padua, Italy
700    1_
$a Mussolin, Lara $u Maternal and Child Health, Department Pediatric Hematology, Oncology and Stem Cell Transplant Center, University of Padua, Padua, Italy $u Pediatric Research Institute "Città della Speranza", Padua, Italy
700    1_
$a Janikova, Andrea $u Center of Molecular Medicine, Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Pospíšilová, Šárka $u Center of Molecular Medicine, Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Turner, Suzanne D $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK $u Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000284394507
700    1_
$a Inghirami, Giorgio $u Weill Cornell Medicine, New York, NY, USA
700    1_
$a Magni, Fulvio $u Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
700    1_
$a Urso, Mario $u Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy $u Department of Pathology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
700    1_
$a Pagni, Fabio $u Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy $u Department of Pathology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
700    1_
$a Ramazzotti, Daniele $u Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy $1 https://orcid.org/0000000260872666
700    1_
$a Piazza, Rocco $u Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
700    1_
$a Chiarle, Roberto $u Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy $u Department of Pathology, Children's Hospital and Harvard Medical School, Boston, MA, USA $u Division of Haematopathology, European Institute of Oncology IRCCS, Milan, Italy
700    1_
$a Gambacorti-Passerini, Carlo $u Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy $u Department of Haematology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
700    1_
$a Mologni, Luca $u Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy. luca.mologni@unimib.it $1 https://orcid.org/0000000263655149
773    0_
$w MED00009369 $t British journal of cancer $x 1532-1827 $g Roč. 131, č. 11 (2024), s. 1781-1795
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39478125 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104101 $b ABA008
999    __
$a ok $b bmc $g 2263123 $s 1239193
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 131 $c 11 $d 1781-1795 $e 20241030 $i 1532-1827 $m British journal of cancer $n Br J Cancer $x MED00009369
GRA    __
$a IG-22082 $p Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
GRA    __
$a 2022XPF8A5 $p Ministero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research)
GRA    __
$a IG-20112 $p Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
GRA    __
$a R01 CA196703 $p NCI NIH HHS $2 United States
GRA    __
$a IG-24828 $p Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace